Home >> Pharmaceuticals >> Food & Beverage >>

Tauopathies - Pipeline Review, H1 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 54 | Code: MRS - 18256

Tauopathies - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Tauopathies - Pipeline Review, H1 2015’, provides an overview of the Tauopathies’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Tauopathies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tauopathies and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Tauopathies
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Tauopathies and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Tauopathies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Tauopathies pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Tauopathies
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Tauopathies pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Tauopathies Overview 7
Therapeutics Development 8
Pipeline Products for Tauopathies - Overview 8
Pipeline Products for Tauopathies - Comparative Analysis 9
Tauopathies - Therapeutics under Development by Companies 10
Tauopathies - Therapeutics under Investigation by Universities/Institutes 11
Tauopathies - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Tauopathies - Products under Development by Companies 14
Tauopathies - Products under Investigation by Universities/Institutes 15
Tauopathies - Companies Involved in Therapeutics Development 16
AbbVie Inc. 16
Bristol-Myers Squibb Company 17
Chronos Therapeutics Limited 18
Prothena Corporation plc 19
Selvita SA 20
SK Biopharmaceuticals Co., Ltd. 21
Summit Therapeutics plc. 22
Tauopathies - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 29
Drug Profiles 31
Antibody to Target Tau Protein for Alzheimer's Disease and Tauopathies - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
BMS-986168 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Gene Therapy for Tauopathies - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Monoclonal Antibodies to Inhibit Tau for Alzheimer's Disease and Tauopathies - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
RDC-5 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SEL-141 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecule for Tauopathies and Alzheimer's Disease - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecule to Inhibit O-linked N-acetylglucosaminidase for Neurodegenerative Diseases - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules for Alzheimer's Disease and Tauopathies - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecules to Inhibit PAR-1 for Neurodegenerative Diseases - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecules to Inhibit Tau for Alzheimer Disease and Tauopathies - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Thiamet-G - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Vaccine to Target Tau for Alzheimer's Disease and Parkinson's Disease - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
YM-08 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Tauopathies - Recent Pipeline Updates 48
Tauopathies - Dormant Projects 50
Tauopathies - Product Development Milestones 51
Featured News & Press Releases 51
Mar 11, 2013: Summit Reports New Data From OGA Inhibitor Program For Treatment Of Tauopathies 51
Aug 02, 2012: Summit Receives £150,000 Grant From Biomedical Catalyst 52
Jul 17, 2012: Summit Presents New Data On OGA Inhibition At Alzheimer's Association International Conference 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54

List of Tables
Number of Products under Development for Tauopathies, H1 2015 8
Number of Products under Development for Tauopathies - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Tauopathies - Pipeline by AbbVie Inc., H1 2015 16
Tauopathies - Pipeline by Bristol-Myers Squibb Company, H1 2015 17
Tauopathies - Pipeline by Chronos Therapeutics Limited, H1 2015 18
Tauopathies - Pipeline by Prothena Corporation plc, H1 2015 19
Tauopathies - Pipeline by Selvita SA, H1 2015 20
Tauopathies - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 21
Tauopathies - Pipeline by Summit Therapeutics plc., H1 2015 22
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Stage and Target, H1 2015 25
Number of Products by Stage and Mechanism of Action, H1 2015 27
Number of Products by Stage and Route of Administration, H1 2015 28
Number of Products by Stage and Molecule Type, H1 2015 30
Tauopathies Therapeutics - Recent Pipeline Updates, H1 2015 48
Tauopathies - Dormant Projects, H1 2015 50

List of Figures
Number of Products under Development for Tauopathies, H1 2015 8
Number of Products under Development for Tauopathies - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Top 10 Targets, H1 2015 24
Number of Products by Stage and Top 10 Targets, H1 2015 25
Number of Products by Top 10 Mechanism of Actions, H1 2015 26
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 27
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 28
Number of Products by Top 10 Molecule Types, H1 2015 29
Number of Products by Stage and Top 10 Molecule Types, H1 2015 30

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing